Table 4 Ocular and side effect characteristic of biological treatment mechanism groups.
From: Ocular side effects of novel anti-cancer biological therapies
Variable | Group 1 N (%) | Group 2 N (%) | Group 3 N (%) | Group 4 N (%) | p value (χ2) |
|---|---|---|---|---|---|
Past ocular history | 0.081 | ||||
Cataract | 4 (40) | 5 (100) | 1 (33.3) | 1 (25) | |
ERM | 0 (0) | 1 (20) | 0 (0) | 0 (0) | |
CSR | 0 (0) | 0 (0) | 1 (33.3) | 0 (0) | |
Side effects | 0.219 | ||||
posterior, panuveitis) | 4 (40) (3, 0, 1) | 3 (60) (2, 1, 0) | 0 (0) (0, 0, 0) | 2 (50) (2, 0, 0) | |
CSR-like | 3 (30) | (0) | 1 (33.3) | 1 (25) | |
Dry eye | 2 (20) | 2 (40) | 0 (0) | 1 (12.5) | |
Vitreitis | 2 (20) | 0 (0) | 0 (0) | 0 (0) | |
CRAO | 0 (0) | 1 (20) | 0 (0) | 0 (0) | |
CME | 1 (10) | 0 (0) | 0 (0) | 0 (0) | |
Trichomegaly | 0 (0) | 0 (0) | 2 (66.6) | 1 (25) | |
BRVO | 0 (0 | 1 (20) | 0 (0) | 0 (0) | |
Treatment | 0.325 | ||||
Intravitreal injection | 2 | 1 | 0 | 0 | |
Topical | 5 | 4 | 0 | 3 | |
Medical | 1 | 0 | 0 | 0 | |
Surgical | 1 | 0 | 0 | 0 |
